Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
Recruitment status was Recruiting
The activity of monotherapy with Lenalidomide will be evaluated in patients with lymphoma of the mucosa associated lymphoid tissue (MALT).
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type|
- Rate of objective responses induced by Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: No ]
- Time to progression [ Time Frame: 24 months ] [ Designated as safety issue: No ]
|Study Start Date:||July 2009|
|Estimated Study Completion Date:||June 2011|
|Estimated Primary Completion Date:||June 2011 (Final data collection date for primary outcome measure)|
Lenalidomide administered orally at a dose of 25 mg daily
25 mg Lenalidomide p.o. daily for 21 days
The primary objective of the study is to evaluate the clinical potential of Lenalidomide to induce objective/histologic responses in patients with MALT lymphoma.
The secondary objectives are to evaluate the safety of Lenalidomide in this patient population and to evaluate the impact of Lenalidomide on progression free survival.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00923663
|Contact: Markus Raderer, MD||+43-1-40400 ext email@example.com|
|Dept of Internal Medicine||Recruiting|
|Vienna, Austria, A-1090|
|Contact: Markus Raderer, MD +43-1-40400 ext 2296 firstname.lastname@example.org|
|Principal Investigator: Markus Raderer, MD|